- Home
- LFWD vs SYBX Comparison
LFWD vs SYBX Comparison
Compare LFWD & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- SYBX
- Stock Information
- Founded
- LFWD 2001
- SYBX N/A
- Country
- LFWD Israel
- SYBX United States
- Employees
- LFWD N/A
- SYBX N/A
- Industry
- LFWD
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- SYBX Health Care
- Exchange
- LFWD NYSE
- SYBX Nasdaq
- Market Cap
- LFWD 20.0M
- SYBX 17.0M
- IPO Year
- LFWD 2014
- SYBX N/A
- Fundamental
- Price
- LFWD $1.45
- SYBX $1.42
- Analyst Decision
- LFWD Strong Buy
- SYBX Hold
- Analyst Count
- LFWD 1
- SYBX 3
- Target Price
- LFWD $13.00
- SYBX $1.00
- AVG Volume (30 Days)
- LFWD 83.7K
- SYBX 74.6K
- Earning Date
- LFWD 11-12-2024
- SYBX 11-12-2024
- Dividend Yield
- LFWD N/A
- SYBX N/A
- EPS Growth
- LFWD N/A
- SYBX N/A
- EPS
- LFWD N/A
- SYBX N/A
- Revenue
- LFWD $25,002,000.00
- SYBX $2,777,000.00
- Revenue This Year
- LFWD $87.01
- SYBX N/A
- Revenue Next Year
- LFWD $47.64
- SYBX N/A
- P/E Ratio
- LFWD N/A
- SYBX N/A
- Revenue Growth
- LFWD 173.28
- SYBX 292.23
- 52 Week Low
- LFWD $1.41
- SYBX $1.22
- 52 Week High
- LFWD $9.10
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- LFWD 26.66
- SYBX 48.54
- Support Level
- LFWD $1.41
- SYBX $1.36
- Resistance Level
- LFWD $1.55
- SYBX $1.88
- Average True Range (ATR)
- LFWD 0.14
- SYBX 0.09
- MACD
- LFWD -0.02
- SYBX -0.01
- Stochastic Oscillator
- LFWD 7.02
- SYBX 11.54
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.